FDA has issued warning to Reviva Labs, a Jersey based cosmetic re-packer and labeler, as well as a re-labeler of over-the-counter (OTC) drug products, for creating misleading projections. FDA inspected the facility of the firm and served notice to remove the misleading labels on products and onsite contents.
FDA objected to using terms like : “reduces blemish-causing bacteria”, “reduce inflammation”, “reduces blemish-causing bacteria..”, “effective treatment for brown spots and other skin discolorations”, “diminish dark spots” and many more. This unapproved language on labels creates the impression that these cosmetic products are very effective like drugs, whereas FDA has strict procedure before any product can be labelled and sold as drug, and it approves a new drug only on the basis of scientific data and information demonstrating that the drug is safe and effective as per claim.
FDA has been vigilant to ensure that cosmetic manufacturers do not market their products unethically by promoting them like drugs. On the other hand, the cosmetic companies have been trying to circumvent FDA regulations, and promote their products as “new formulae”, “new treatment”, and so on. This is particularly rampant among online suppliers of cosmetic items.
The other unfair practice of many players is that they do not display the ingredients on the labels, though making all kinds of unverifiable claims, and marketing them with attractive glamorous marketing campaigns.
Although FDA has asked Reviva Labs to “take prompt action to correct the violations” failing which may result in legal action, the consumers also need to exercise caution, and satisfy themselves of the reliability and efficacy of the cosmetics they choose to buy.